Nessan Bermingham
Person ● Covered in 0 stories + Follow ✴ AI Graph Request update
Nessan Bermingham is an Operating Partner at Khosla Ventures, where he focuses on life science companies, including nucleic acid editing, delivery systems, gene and cell therapy, target identification, and data analytics for drug discovery and development. He previously held investment roles at Atlas Venture and Omega Fund Management and earlier was a member of the equity research team at UBS. Bermingham has founded multiple life sciences companies, including Intellia Therapeutics, Triplet Therapeutics, and Korro Bio; at Intellia, he served as president and CEO from its inception through 2017 and led the company through partner deals, financing rounds, and its IPO. He is also currently executive chair at Everyone Medicines and Korro Bio and is known for building and investing in biotech companies.
Updated 8 September 2026
Public sources: khoslaventures.com
Why this page exists, and how to correct or remove it
This profile is assembled automatically because Nessan Bermingham appears in coverage we index or holds a role listed publicly by their organisation. It uses only public sources — company and organisation pages, news articles, Wikipedia, and public professional listings — and the biography, if any, is written by AI from those sources and cited above.
We hold it to report on the AI industry, under the legitimate interest of journalistic reporting. You can ask us to correct it, restrict it, or take it down, and you can object at any time — no account needed, no reason required.
Claim or correct this profile Request removal How we handle personal data